Navigation Links
Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
Date:3/8/2010

DENVER, March 8 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: CHYE) is pleased to announce today that the Company has retained California-based Redwood Consultants, LLC to assist in shareholder relations and investor communications.

Ampio Pharmaceuticals, Inc. CEO Don Wingerter said, "We are delighted to announce our relationship with Redwood Consultants. We are committed to providing timely and consistent updates to the investment community. We will be working closely with senior management of Redwood to keep the global investment community apprised of our progress at all levels."

Redwood Consultants Managing Director, Jens Dalsgaard commented, "We believe Ampio has the potential to be a billion dollar company. Their strong product pipeline and seasoned management team can provide investors significant milestones both near and long term. With several hundred discoveries and high quality research capabilities, Chief Scientific Officer Dr. Bar-Or has over 80 publications in referenced Journals, over 50 published patents and 119 patent applications. The Ampio team has uncovered a range of discoveries beneficial to many areas of medical practice including diagnostic medicine, immune therapy, diabetes, particularly diabetic retinopathy, neurology, cardiology and oncology. We are elated to be working with Ampio and look forward to frequent investor updates."

About Redwood Consultants, LLC

Redwood Consultants, LLC is a full-service investor relations firm that works closely with emerging, publicly traded companies to communicate their value to the investment community and build and sustain greater investor sponsorship. We are committed to our clients' success. Our mission is to deliver highly credible information and comprehensive research on the corporate potential of the emerging companies we represent to the Wall Street community of analysts, institutional investors and retail stockbrokers. Redwood Consultants recognizes that small, innovative companies must align themselves with a trusted investor relations partner to successfully compete in today's new-market environment. We are known throughout the financial community for our loyalty, integrity and credibility. For more information, see www.redwoodconsultants.com.

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc is a Denver based bio technology firm with a long relationship with the Swedish Medical Center.  With several hundred discoveries, high quality research capabilities and access to extensive clinical data, Ampio is developing exciting pharmaceutical products and medical devices.

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

SOURCE Ampio Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.ampiopharma.com

'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
2. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
3. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
6. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
7. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
8. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
9. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
10. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
11. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- International Biophysics Corporation, a global medical device manufacturer based in ... revenue growth in 2016 when compared to the previous year ... was fueled by its AffloVest® sales in the ... its global sales of surgical product lines. Said ... our 25 th year in delivering high-quality, innovative medical ...
(Date:2/27/2017)... Calif. , Feb. 27, 2017   Vitasome ... line of nutritional supplements using its groundbreaking new liposome ... 90 percent of potency through digestion per Physician,s ... supplements solve the problem of nutritional waste and are ... degradation during digestive processes Improve bioavailability ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... muscle mass and overall body strength, which often leads to a host of ... Journal of the American Geriatrics Society discovered that good overall muscle ...
(Date:2/27/2017)... ... 27, 2017 , ... Much attention has been paid to the problem of ... opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain ... overdoses in male populations.(1) , The proportion of women using illicit drugs is also ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... on laser diffraction analysis as a tool to characterize particle size distributions in ... to obtain improved results and novel scientific findings. It describes methods of optimized ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/26/2017)... ... ... The February 13, 2017, assassination of Kim Jong-nam, the half brother of ... deadly use of chemical weapons. Many questions exist about the effect that nerve agents ... lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, and one of the ...
Breaking Medicine News(10 mins):